Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IDH305 |
Synonyms | |
Therapy Description |
IDH305 specifically targets IDH1 with mutations at amino acid R132, which results in decreased 2HG production and potentially leads to increased differentiation and decreased proliferation of IDH R132-mutant cancer cells (PMID: 29057061). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IDH305 | IDH 305|IDH-305 | IDH1 Inhibitor 8 | IDH305 specifically targets IDH1 with mutations at amino acid R132, which results in decreased 2HG production and potentially leads to increased differentiation and decreased proliferation of IDH R132-mutant cancer cells (PMID: 29057061). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 R132X | acute myeloid leukemia | sensitive | IDH305 | Phase I | Actionable | In a Phase I trial, IDH305 treatment resulted in objective response in 33% (7/21) of acute myeloid leukemia patients harboring IDH1 R132 mutations, including complete remission in 3 (14%) and partial remission in 4 (19%) patients (Blood 2016 128 (22):1073). | detail... |
IDH1 R132H IDH1 T313I | leukemia | predicted - resistant | IDH305 | Preclinical - Biochemical | Actionable | In a preclinical study, IDH305 did not inhibit R-2HG production in a leukemia cell line expressing IDH1 R132H and T313I in culture (PMID: 36222845). | 36222845 |
IDH1 R132H IDH1 H315D | leukemia | predicted - resistant | IDH305 | Preclinical - Biochemical | Actionable | In a preclinical study, IDH305 did not inhibit R-2HG production in a leukemia cell line expressing IDH1 R132H and H315D in culture (PMID: 36222845). | 36222845 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02977689 | Phase II | IDH305 | Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | Withdrawn | USA | 0 |
NCT02381886 | Phase I | IDH305 | A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | Active, not recruiting | USA | NLD | ESP | DEU | CAN | BEL | AUS | 1 |